BACKGROUND AND OBJECTIVES: We assessed the activation of the oxidative stress pathway in patients with IgA nephropathy (IgAN), while evaluating the classic marker of the disease (galactose-deficient serum IgA1). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sera from 292 patients and 69 healthy controls from Italy and the United States were assayed for advanced oxidation protein products (AOPPs), free sulfhydryl groups on albumin (SH-Alb), and IgA1 with galactose-deficient hinge-region O-glycans (Gd-IgA1). Gd-IgA1 was detected by binding to Helix aspersa agglutinin (HAA) and expressed as total Gd-IgA1 or as degree of galactose deficiency relative to a standard Gd-IgA1 myeloma protein (%HAA). RESULTS: Sera from IgAN patients showed higher levels of Gd-IgA1, %HAA, and AOPPs, but lower levels of SH-Alb in comparison to that from healthy controls. Serum levels of AOPPs significantly correlated with serum Gd-IgA1 and %HAA. The relationship between these biomarkers and clinical features at sampling and during follow-up was assessed in 62 patients with long-term follow-up. AOPPs and %HAA correlated with proteinuria at sampling and independently associated with subsequent proteinuria. Levels of AOPPs correlated with rate of decline in renal function after sampling. The combination of a high level of AOPPs and a high level of %HAA associated with decline in estimated GFR. CONCLUSIONS: Serum levels of aberrantly glycosylated IgA1 are elevated and oxidative stress pathways are activated in patients with IgAN; the intensity of the stress correlated with expression and progression of the disease. We speculate that oxidative stress may modulate the nephrotoxicity of aberrantly glycosylated IgA1 in IgAN.
BACKGROUND AND OBJECTIVES: We assessed the activation of the oxidative stress pathway in patients with IgA nephropathy (IgAN), while evaluating the classic marker of the disease (galactose-deficient serum IgA1). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sera from 292 patients and 69 healthy controls from Italy and the United States were assayed for advanced oxidation protein products (AOPPs), free sulfhydryl groups on albumin (SH-Alb), and IgA1 with galactose-deficient hinge-region O-glycans (Gd-IgA1). Gd-IgA1 was detected by binding to Helix aspersa agglutinin (HAA) and expressed as total Gd-IgA1 or as degree of galactose deficiency relative to a standard Gd-IgA1myeloma protein (%HAA). RESULTS: Sera from IgANpatients showed higher levels of Gd-IgA1, %HAA, and AOPPs, but lower levels of SH-Alb in comparison to that from healthy controls. Serum levels of AOPPs significantly correlated with serum Gd-IgA1 and %HAA. The relationship between these biomarkers and clinical features at sampling and during follow-up was assessed in 62 patients with long-term follow-up. AOPPs and %HAA correlated with proteinuria at sampling and independently associated with subsequent proteinuria. Levels of AOPPs correlated with rate of decline in renal function after sampling. The combination of a high level of AOPPs and a high level of %HAA associated with decline in estimated GFR. CONCLUSIONS: Serum levels of aberrantly glycosylated IgA1 are elevated and oxidative stress pathways are activated in patients with IgAN; the intensity of the stress correlated with expression and progression of the disease. We speculate that oxidative stress may modulate the nephrotoxicity of aberrantly glycosylatedIgA1 in IgAN.
Authors: Ali G Gharavi; Zina Moldoveanu; Robert J Wyatt; Catherine V Barker; Susan Y Woodford; Richard P Lifton; Jiri Mestecky; Jan Novak; Bruce A Julian Journal: J Am Soc Nephrol Date: 2008-02-13 Impact factor: 10.121
Authors: Hitoshi Suzuki; Zina Moldoveanu; Stacy Hall; Rhubell Brown; Huong L Vu; Lea Novak; Bruce A Julian; Milan Tomana; Robert J Wyatt; Jeffrey C Edberg; Graciela S Alarcón; Robert P Kimberly; Yasuhiko Tomino; Jiri Mestecky; Jan Novak Journal: J Clin Invest Date: 2008-02 Impact factor: 14.808
Authors: J Mestecky; M Tomana; Z Moldoveanu; B A Julian; H Suzuki; K Matousovic; M B Renfrow; L Novak; R J Wyatt; J Novak Journal: Kidney Blood Press Res Date: 2008-01-08 Impact factor: 2.687
Authors: Z Moldoveanu; R J Wyatt; J Y Lee; M Tomana; B A Julian; J Mestecky; W-Q Huang; S R Anreddy; S Hall; M C Hastings; K K Lau; W J Cook; J Novak Journal: Kidney Int Date: 2007-03-07 Impact factor: 10.612
Authors: Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt Journal: Expert Opin Med Diagn Date: 2013-11
Authors: Francois Berthoux; Hitoshi Suzuki; Lise Thibaudin; Hiroyuki Yanagawa; Nicolas Maillard; Christophe Mariat; Yasuhiko Tomino; Bruce A Julian; Jan Novak Journal: J Am Soc Nephrol Date: 2012-08-16 Impact factor: 10.121